Accessibility Menu
Basilea Pharmaceutica Ag logo

Basilea Pharmaceutica Ag(OTC) BPMUF

Market Cap$747.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+19%
5 Year+31%
1 Year+4%
1 Month-13%
$60.28
+0.00%
+0.00Today
Basilea Pharmaceutica Ag last closing stock price
MetricPriceDate
Last closeUSD 60.282026-06-10
Basilea Pharmaceutica Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.41%USD 65.102026-05-18
1 month-12.64%USD 69.002026-04-23
3 month-15.11%USD 71.002026-01-30
Year to date-4.7%USD 63.252025-12-04
1 year+4.46%USD 57.702025-06-06
3 year+20.55%USD 50.002023-06-08
5 year+30.93%USD 46.042021-05-14
Since inception+19.36%USD 50.502004-08-24

Basilea Pharmaceutica Ag Financials at a Glance

Market Cap

$747.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 441.00M

Net Income (TTM)

CHF 117.80M

EPS (TTM)

$3.67

P/E Ratio

15.13

Dividend

$0.00

Beta (Volatility)

-0.01 (Low)

Price

$60.28

Volume

12

Open

$60.28

Previous Close

$60.28

Daily Range

$60.28 - $60.28

52-Week Range

$59.29 - $74.00

Estimated Earnings Date

Aug 18, 2026

BPMUF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Basilea Pharmaceutica Ag

Basilea Pharmaceutica AG is a biopharmaceutical company focused on developing innovative therapies for oncology and infectious diseases. The company generates revenue from its product portfolio, which includes advanced treatments for serious medical conditions.

Products and Services
  • Cresemba: An antifungal drug for invasive aspergillosis and mucormycosis
  • Zevtera: An antibiotic for pneumonia and skin infections
  • Derazantinib: A small molecule inhibitor in trials for bile duct cancer
Growth Outlook
  • Cresemba is in Phase III trials in Japan, expanding market potential
  • Zevtera is advancing through Phase III studies, targeting acute bacterial infections
  • Pipeline includes Lisavanbulin, a promising tumor checkpoint controller
Financial Highlights
  • Recent quarterly revenue of 128.5 million CHF, showing strong growth
  • Net income of 24.4 million CHF in the latest quarter, indicating profitability
  • TTM gross profit margin of 74.3%, reflecting operational efficiency
Basilea Pharmaceutica AG is strategically positioned in the biotechnology sector, focusing on unmet medical needs. The company's innovative products and robust pipeline suggest a commitment to addressing critical health challenges. Recent financial performance highlights a positive trajectory, with significant revenue growth and profitability in the latest quarter. The ongoing clinical trials for key products further enhance the company's growth potential, making it an intriguing option for investors interested in the biopharmaceutical landscape.
AI Generated • Jul 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

189

CEO

David Veitch

Website

www.basilea.com

Headquarters

Allschwil, BL 4123, CH

BPMUF Financials

Key Financial Metrics (TTM)

Gross Margin

74.32%

Operating Margin

21.94%

Net Income Margin

17.90%

Return on Equity

27.95%

Return on Capital

23.77%

Return on Assets

11.45%

Earnings Yield

6.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$747.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.40M

Volume

12

Avg. Volume

0.365

Financials (TTM)

Gross Profit

CHF 324.72M

Operating Income

CHF 112.79M

EBITDA

CHF 120.81M

Operating Cash Flow

CHF 136.47M

Capital Expenditure

-CHF 4.41M

Free Cash Flow

CHF 132.06M

Cash & ST Invst.

CHF 162.41M

Total Debt

CHF 89.22M

Basilea Pharmaceutica Ag Performance Analysis

Basilea Pharmaceutica Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 154,717,199-4.5%
20232023-12-31CHF 175,411,66513.4%
20242024-12-31CHF 236,801,04535.0%
20252025-12-31CHF 279,811,98118.2%
Basilea Pharmaceutica Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-304.9%
Q42024-12-3173.3%
Q22025-06-30-21.4%
Q42025-12-3123.6%
Basilea Pharmaceutica Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF 1.06N/A
20232023-12-31CHF 0.96-10.1%
20242024-12-31CHF 6.61590.6%
20252025-12-31CHF 3.78-42.8%
Basilea Pharmaceutica Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30184.3%
Q42024-12-31180.0%
Q22025-06-30-70.0%
Q42025-12-3158.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CHF 128.50M

+76.7%

Gross Profit

CHF 113.42M

+102.8%

Gross Margin

88.27%

N/A

Market Cap

$747.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.95M

N/A

Employees

189

N/A

Net Income

CHF 24.41M

+214.1%

EBITDA

CHF 29.37M

+833.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CHF 162.41M

+171.1%

Total Debt

CHF 89.22M

-30.6%

Accounts Receivable

CHF 63.31M

+127.0%

Inventory

CHF 21.57M

-18.3%

Long Term Debt

CHF 87.16M

-21.5%

Short Term Debt

CHF 2.06M

-88.2%

Return on Assets

11.45%

N/A

Return on Invested Capital

17.00%

N/A

Free Cash Flow

CHF 36.75M

+544.7%

Operating Cash Flow

CHF 39.05M

+612.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SOLTFNxera Pharma Co., Ltd.
$5.73+1.74%
INRLFValneva SE
$2.43+0.00%
PTCHFPureTech Health plc
$1.53+0.00%
VBIZFViva Biotech Holdings
$0.16+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About BPMUF

What is the current price of Basilea Pharmaceutica Ag?

Basilea Pharmaceutica Ag is trading at $60.28 per share.

What is the 52-week range for Basilea Pharmaceutica Ag?

Over the past 52 weeks, Basilea Pharmaceutica Ag has traded between $59.29 and $74.00.

How much debt does Basilea Pharmaceutica Ag have?

As of the most recent reporting period, Basilea Pharmaceutica Ag reported total debt of CHF 112.61M.

How much cash does Basilea Pharmaceutica Ag have on hand?

Basilea Pharmaceutica Ag reported CHF 37.41M in cash and cash equivalents in its most recent financial results.

What is Basilea Pharmaceutica Ag’s dividend yield?

Basilea Pharmaceutica Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services